BioNTech lifts 2025 revenue guidance on BMS partnership payment

Core Viewpoint - Germany's BioNTech has raised its 2025 revenue guidance following initial payments from Bristol Myers Squibb for a cancer immunotherapy partnership aimed at competing with Merck's Keytruda [1] Group 1 - BioNTech's new partnership with Bristol Myers Squibb focuses on cancer immunotherapy [1] - The collaboration is intended to challenge the market dominance of Merck's Keytruda, which is currently the best-selling cancer treatment [1] - The increase in revenue guidance indicates positive financial expectations for BioNTech as a result of this alliance [1]